Source: KP Albumin: Better Than Crystalloid in Septic Shock? Human albumin boosts oncotic pressure, and has a number of important biologic functions (protein binding, antioxidant, etc.) that could in theory support the body during critical illness. In the 2004 SAFE study, which tested albumin against crystalloid solutions in ~7,000 critically ill patients of various etiologies, 4% [... read more]
The post Albumin for severe sepsis and septic shock: More confusing findings (ALBIOS Trial) appeared first on PulmCCM.
PulmCCM Roundup #3 All the best in pulmonary and critical care we’ve found lately. Browse all the PulmCCM Roundups. Surviving Sepsis Campaign Responds to ProCESS Trial In the wake of the ProCESS trial demonstrating no benefit from use of protocols for septic shock, the Surviving Sepsis Campaign released a statement in which they “continue to recommend [... read more]
The post PulmCCM Roundup #3 appeared first on PulmCCM.
Image: EKOS Patients with acute pulmonary embolism (PE) fall into three general clinical categories: Massive PE, most often defined as hypotension due to right ventricular dysfunction. Short-term mortality is high (more than 1 in 7 die in-hospital). Systemic thrombolytic therapy (tissue plasminogen activator or tPA) is considered standard care by AHA and ACCP, because it [... read more]
The post Catheter directed thrombolysis for submassive PE: better than heparin? (RCT) appeared first on PulmCCM.
PulmCCM Roundup #2 Welcome back to the PulmCCM Roundup, formerly the Critical Care Roundup. Let’s jump right in to issue #2. Browse all the PulmCCM Roundups here. Etomidate for intubation in sepsis: what’s the risk, really? Etomidate has been suspected of causing adrenal insufficiency and potentially death in patients with severe sepsis, when used as an anesthesia-induction agent [... read more]
The post PulmCCM Roundup, Issue #2 appeared first on PulmCCM.
FDA Warning on Doripenem (Doribax) for VAP In March 2014, the FDA issued a warning statement against Doribax (doripenem) for ventilator associated pneumonia, saying: Doribax carries an increased risk of death and lower clinical cure rates compared to use of imipenem and cilastatin … Doribax is not approved to treat any type of pneumonia. (Doripenem is approved [... read more]
The post FDA warns against doripenem (Doribax) for ventilator-associated pneumonia appeared first on PulmCCM.
In Septic Shock, Goal of MAP > 65 mm Hg Remains Standard by Abhishek Biswas, MD In the 13 years since Rivers et al published their seminal paper that established “early goal directed therapy” for sepsis as the standard of care, treatment for severe sepsis and septic shock have evolved dramatically. Newer research questions the wisdom [... read more]
The post No benefit from higher mean arterial pressure in most with septic shock appeared first on PulmCCM.